Low-Dose Testosterone and Rosuvastatin Interaction: What Women Need to Know

Why This Combination Comes Up in Women's Health

Two drugs that rarely appear on the same prescription pad for men end up together surprisingly often in postmenopausal women's care. Rosuvastatin is one of the most widely prescribed statins globally, taken by roughly one in four women over 55 in the United States for cardiovascular risk reduction. Low-dose compounded testosterone is prescribed off-label in the US to treat hypoactive sexual desire disorder (HSDD) and general symptoms of androgen insufficiency in postmenopausal and surgically menopausal women, a use supported by The Menopause Society's 2023 position statement.

Because HSDD affects an estimated 40% of postmenopausal women, and because cardiovascular risk climbs sharply after menopause, these two prescriptions land in the same medicine cabinet far more often than most clinicians anticipate.

The question is not just "is it safe?" The question is "what exactly happens pharmacologically, and how do you watch for it?"

The Pharmacokinetic Mechanism: OATP1B1 and Hepatic Uptake

Rosuvastatin's primary route into the liver, where it does its job inhibiting HMG-CoA reductase, is carrier-mediated uptake by the organic anion transporting polypeptides OATP1B1 and OATP1B3. It undergoes minimal CYP450 metabolism (roughly 10% via CYP2C9) and is not a P-glycoprotein substrate. This makes rosuvastatin unusually sensitive to anything that competes for or inhibits OATP1B1.

Testosterone and its metabolites, including estradiol formed peripherally from testosterone by aromatase, have been shown to interact with OATP1B1 in vitro. A 2015 study in Drug Metabolism and Disposition demonstrated that endogenous androgens and estrogens can inhibit OATP1B1-mediated transport of rosuvastatin, with IC50 values suggesting clinically relevant competition at physiologic to supraphysiologic concentrations.

What This Means for Rosuvastatin Levels

When OATP1B1 uptake into hepatocytes is partially blocked, rosuvastatin remains longer in systemic circulation. The result is a rise in the area under the concentration-time curve (AUC). For perspective: the potent OATP1B1 inhibitor gemfibrozil can increase rosuvastatin AUC by as much as 2-fold, which is why the FDA label for rosuvastatin recommends capping the dose at 10 mg/day when the two are co-prescribed. Testosterone is a weaker OATP1B1 inhibitor than gemfibrozil, so the magnitude of AUC increase at female physiologic doses (free testosterone target: 0.5 to 2.5 pg/mL) is expected to be small, probably 10 to 30%. No dedicated pharmacokinetic study has measured this precisely in women on low-dose transdermal testosterone. That evidence gap matters and is addressed in a later section.

CYP450: Less of a Concern Here

Unlike many drug interactions involving statins, CYP enzymes are not the main story here. Rosuvastatin is not meaningfully metabolized by CYP3A4. Testosterone is primarily metabolized by CYP3A4 and CYP3A5, but because rosuvastatin is not a substrate, CYP-mediated interactions between these two drugs are not expected to be clinically significant.

The Pharmacodynamic Concern: Shared Muscle Toxicity Risk

Beyond pharmacokinetics, both drugs independently carry a risk of muscle injury. This matters more when they are combined.

Statin-Related Myopathy in Women

Statins cause a spectrum of muscle effects, from mild myalgia (muscle pain without CK elevation) to rare but serious rhabdomyolysis. Women may be at modestly higher risk than men for statin-induced myopathy, though the data are mixed. A 2019 analysis in the Journal of Clinical Lipidology found that female sex, lower body weight, and hypothyroidism were independently associated with statin myopathy risk. Postmenopausal women, who are the target population for testosterone HSDD therapy, often have one or more of these risk factors simultaneously.

Testosterone and Muscle: Protective or Problematic?

Testosterone at physiologic doses is generally anabolic for muscle and bone, and some data suggest it may be protective against myopathy rather than additive to it. A 2019 randomized trial in JAMA Internal Medicine found that transdermal testosterone improved muscle mass and physical function in older women with low androgen levels. Supraphysiologic doses, however, could theoretically stress muscle metabolically. At the low doses used for HSDD (target serum free testosterone within or just above the premenopausal reference range), frank androgen-induced myopathy is not a documented concern in women. The risk is additive rather than synergistic, and clinically small.

Testosterone's Effect on the Lipid Panel

This is a pharmacodynamic interaction you will see on the lab sheet. Testosterone at any dose tends to shift the lipid profile in a direction that can partially counteract rosuvastatin's work.

HDL Reduction

The most consistent finding across studies is that testosterone lowers HDL cholesterol. A 2014 Cochrane review of testosterone therapy in women reported a mean HDL reduction of approximately 6% with systemic testosterone use. Transdermal delivery at low doses causes smaller shifts than oral or injectable formulations because it avoids first-pass hepatic effects. Compounded transdermal testosterone at 0.5 to 2 mg/day is likely to cause HDL changes of 2 to 5%, which may be partially offset by rosuvastatin's modest HDL-raising effect.

LDL and Triglycerides

Low-dose transdermal testosterone has a smaller and less consistent effect on LDL and triglycerides compared with oral formulations. The 2019 ISSWSH and NAMS Position Statement on Testosterone in Women notes that transdermal routes are preferred precisely because they produce fewer adverse lipid changes.

Rosuvastatin typically reduces LDL by 38 to 55% at doses of 10 to 40 mg/day, a magnitude that easily covers any LDL increase from low-dose testosterone. The net lipid impact of the combination in a postmenopausal woman is likely dominated by the statin.

Sex-Specific Physiology: Why Female Pharmacokinetics Change the Picture

Women differ from men in ways that shape how both drugs behave, and most pharmacokinetic studies of both testosterone and rosuvastatin were conducted in predominantly male or mixed-sex cohorts with inadequate sex-stratified reporting.

Rosuvastatin PK in Women

Women have consistently higher plasma rosuvastatin concentrations than men at equivalent doses. A sex-difference analysis cited in the FDA rosuvastatin prescribing information showed that women had a mean 2-fold higher AUC than men. The FDA label attributes this to differences in body composition and possibly OATP1B1 activity. This means that postmenopausal women on rosuvastatin 20 mg/day may already have rosuvastatin exposures equivalent to a man on 40 mg/day, well before testosterone is added to the mix.

This is not widely appreciated in clinical practice. A woman's baseline rosuvastatin AUC is already elevated relative to the doses used in the cardiovascular outcome trials (JUPITER, for example, enrolled 17,802 participants with a median age of 66, and sex-stratified PK data from JUPITER were not published).

Testosterone PK in Women

Free testosterone at doses of 0.5 to 2 mg/day transdermal in postmenopausal women achieves serum free testosterone in the range of 0.5 to 2.5 pg/mL, within or slightly above the premenopausal reference range. Sex hormone-binding globulin (SHBG) is the dominant modulator. Postmenopausal women on oral estrogen (not transdermal) have markedly elevated SHBG, which will blunt free testosterone bioavailability and may require a slightly higher total testosterone dose to achieve the same free fraction. This interaction between concomitant estrogen route and free testosterone bioavailability is often missed.

Life Stage: Who Is Actually Taking Both Drugs?

Postmenopausal Women (Primary Population)

This is the population where the combination is most common and best studied. Testosterone for HSDD is indicated in postmenopausal women per the 2023 Menopause Society position statement, and cardiovascular risk rises sharply after menopause, making statin prescribing more common. The interaction risks described above are relevant primarily here.

Perimenopausal Women

Perimenopause brings fluctuating estrogen and a gradual decline in free testosterone. Some clinicians prescribe low-dose testosterone off-label for libido, energy, and cognitive symptoms in this group. Statin prescribing is less common in women in their mid-40s unless familial hypercholesterolemia or prior cardiovascular events are present. The interaction is possible but the population overlap is smaller.

Reproductive-Age Women (PCOS, Surgical Menopause)

Women with premature ovarian insufficiency or surgical menopause before age 45 may receive testosterone replacement at reproductive age. Women with PCOS often have elevated endogenous testosterone. In either setting, rosuvastatin co-prescribing is less typical but not impossible.

The frank contraindication in this group is pregnancy. See the mandatory section below.

Trying to Conceive

Testosterone is contraindicated if pregnancy is being pursued or is possible. This cannot be overstated. Any woman in whom testosterone is prescribed must have a reliable contraception plan and must stop testosterone before attempting conception.

Pregnancy, Lactation, and Contraception

Both drugs are contraindicated in pregnancy. Neither is safe during lactation. Reliable contraception is mandatory for any woman of reproductive potential using testosterone.

Testosterone

Testosterone carries an FDA Pregnancy Category X designation. Exogenous androgens cause virilization of female fetuses. Case reports document clitoral hypertrophy, labial fusion, and ambiguous genitalia in female infants born to women who used testosterone during pregnancy. There is no safe dose in pregnancy. Testosterone is secreted in human breast milk; breastfeeding is not recommended during testosterone use, and the Drugs and Lactation Database (LactMed) classifies maternal testosterone use as potentially hazardous to a nursing infant.

Any woman of reproductive potential being prescribed testosterone must use a highly effective contraceptive method (IUD, implant, or combined hormonal method) and must stop testosterone at least 3 months before attempting conception. Serum testosterone should be verified to have returned to baseline before conception is attempted.

Rosuvastatin

Rosuvastatin is also FDA Pregnancy Category X. Statins inhibit cholesterol synthesis, and cholesterol is required for fetal development. Rosuvastatin should be stopped as soon as pregnancy is recognized. Limited data exist on lactation transfer, but the LactMed entry for rosuvastatin notes that statin use is generally contraindicated during breastfeeding given theoretical risk to the nursing infant's lipid metabolism.

Both drugs share the same pregnancy contraindication category. A woman who is prescribed both should have one unified counseling conversation about contraception, not two separate ones.

The Evidence Gap: What We Do Not Know

Transparency about what has not been studied is a trust signal, not a weakness.

No published clinical pharmacokinetic study has directly measured the effect of low-dose compounded transdermal testosterone on rosuvastatin AUC in postmenopausal women. The interaction inference comes from:

1. In vitro OATP1B1 inhibition studies using testosterone and its metabolites.
2. Known sex differences in rosuvastatin pharmacokinetics.
3. Clinical experience with stronger OATP1B1 inhibitors co-prescribed with rosuvastatin.

The 2023 Menopause Society testosterone position statement does not specifically address rosuvastatin co-prescribing. Neither does the FDA rosuvastatin prescribing information specifically call out testosterone. The magnitude of the AUC interaction in women at clinical testosterone doses is extrapolated, not measured.

This matters for how you counsel your patient. The interaction is biologically plausible and supported by mechanistic evidence, but the clinical signal in women at low testosterone doses is theoretical rather than observed in a prospective trial.

Monitoring Protocol for Women on Both Drugs

A structured monitoring plan removes ambiguity and gives your clinician something to act on.

Baseline (Before Starting Testosterone)

• Fasting lipid panel (LDL, HDL, triglycerides, total cholesterol)
• Creatine kinase (CK) if muscle symptoms are present or statin dose is high
• Free testosterone and total testosterone
• SHBG (especially if on oral estrogen therapy)
• Liver function tests (LFTs)
• Blood pressure

At 3 Months

• Free testosterone to confirm therapeutic range (target: within or just above premenopausal reference range per Menopause Society guidance)
• Fasting lipid panel to detect HDL changes
• Symptom review for myalgia, dark urine, or unexplained fatigue

At 6 Months and Annually

• Full lipid panel
• Free testosterone and SHBG
• CK only if symptomatic
• Cardiovascular risk reassessment using a validated tool (e.g., the AHA/ACC Pooled Cohort Equations)

Red-Flag Symptoms That Require Immediate CK Testing

• Muscle pain or weakness that is new or worsening
• Dark or cola-colored urine
• Unexplained fatigue out of proportion to activity

If CK exceeds 10 times the upper limit of normal, rosuvastatin should be held and the prescribing clinician contacted the same day.

Dose Considerations and Practical Adjustments

Should Rosuvastatin Dose Be Capped?

Given that women already have 2-fold higher rosuvastatin AUC than men at equivalent doses, and that testosterone may add a further modest AUC increase, starting or continuing rosuvastatin at the lowest effective dose is reasonable. For most postmenopausal women on low-dose testosterone, a rosuvastatin dose of 5 to 10 mg/day is likely sufficient for LDL targets specified in ACC/AHA cholesterol guidelines. A dose of 40 mg/day in a woman also taking testosterone warrants review of whether that dose is necessary, or whether the target LDL can be achieved at 20 mg/day.

Testosterone Dose: Stay Within Range

Keeping free testosterone within the premenopausal reference range (0.5 to 2.5 pg/mL) minimizes OATP1B1 inhibition and lipid effects. Supraphysiologic testosterone is associated with greater HDL suppression and greater androgenic side effects (acne, hirsutism, clitoral hypertrophy). The compounded dose should be titrated to the lowest dose that achieves symptom benefit.

Route of Testosterone Delivery

Transdermal delivery (gel, cream, or patch) is preferred over oral or injectable routes in women, not just for lipid reasons but for predictability of absorption and avoidance of first-pass hepatic effects. ACOG Practice Bulletin guidance on sexual dysfunction notes that transdermal routes provide more consistent androgen exposure in women.

Who This Combination Is Right For and Not Right For

Likely Appropriate (With Monitoring)

• Postmenopausal women with confirmed HSDD who have not responded to non-hormonal interventions, are already on rosuvastatin at 5 to 20 mg/day, and have no personal history of rhabdomyolysis or severe statin myopathy
• Women with surgical menopause before age 50 who need androgen replacement and cardiovascular risk management simultaneously

Requires Extra Caution

• Women on rosuvastatin 40 mg/day: the already-elevated AUC plus even a modest testosterone-mediated increase warrants a frank conversation about whether 40 mg/day is necessary
• Women with hypothyroidism: hypothyroidism independently raises statin myopathy risk; untreated or undertreated thyroid disease should be addressed before adding testosterone
• Women on cyclosporine (a potent OATP1B1 inhibitor) who are also on rosuvastatin: adding testosterone creates a three-way OATP interaction that requires specialist input

Not Appropriate

• Pregnant women or women attempting conception (both drugs are FDA Pregnancy Category X)
• Women breastfeeding
• Women with active liver disease (testosterone is hepatically metabolized; rosuvastatin AUC is further elevated in hepatic impairment)
• Women with a prior episode of statin-induced rhabdomyolysis

Counseling Points for Your Appointment

At WomanRx, our clinical reviewer Dr. Rachel Goldberg summarizes the key message for patients this way: "For a postmenopausal woman already doing well on rosuvastatin who wants to try testosterone for HSDD, the interaction is real but manageable. We keep the testosterone dose in range, we check a lipid panel and free testosterone at three months, and we tell her exactly what muscle symptoms to report. That is a conversation that takes ten minutes and prevents almost all the preventable problems."

This counseling checklist covers the essentials:

• Tell your prescriber you are on rosuvastatin before starting testosterone.
• Know your current rosuvastatin dose. Doses above 20 mg/day deserve a second look when testosterone is added.
• Expect your HDL to dip slightly. A follow-up lipid panel at three months is not optional.
• Report any new muscle pain, especially with dark urine, immediately.
• If you are using oral estrogen alongside testosterone, your SHBG will be elevated. Your free testosterone needs to be measured, not just total testosterone.
• Testosterone is teratogenic. If there is any chance of pregnancy, contraception is non-negotiable.
• Compounded testosterone is not FDA-approved for women in the US. Ask your prescriber about the specific compounding pharmacy's certificate of analysis and standardized dosing.